Bvax in Prostate Cancer: A B‑Cell Therapy That Penetrates Immune‑Excluded Tumors

A new type of cancer treatment called Bvax is drawing attention in prostate cancer because it may be able to reach inside tumors that are hard to treat with standard immunotherapies. Bvax is made from a patient’s own B cells, which are activated and loaded with tumor‑related proteins, then given back to the body. Once inside, these cells can act both as immune activators and as antibody‑producing cells that help the immune system recognize and attack cancer.

In a mouse model of prostate cancer designed to mimic the kind of tumor that does not respond well to immunotherapy, Bvax treatment reduced tumor volume by 68% at its best effect, compared with untreated animals. This happened even though the prostate tumors were immune‑excluded, meaning few immune cells normally get inside. At the same time, more MHC‑II–positive B cells entered the tumor, suggesting that Bvax helps bring immune activity directly into the tumor tissue instead of leaving it stuck at the edges.

Beyond shrinking the tumor, Bvax also seems to change the immune landscape around it. In other solid‑tumor models, Bvax has been shown to increase a special type of CD8⁺ T cell that has high TCF‑1 and low PD‑1, which is linked to better persistence and response to treatment. This kind of T‑cell behavior is relevant in prostate cancer, where immune cells often become tired or are kept out of the tumor. By producing antibodies that target proteins involved in cell movement and tissue structure, Bvax may also disrupt some of the processes that help prostate cancer spread and invade surrounding tissues, even if the exact prostate model used was not fully natural.

On the clinical side, Bvax is being tested in a Phase 1 trial for newly diagnosed glioblastoma at Northwestern University, using a personalized approach: B cells are taken from the patient, activated, loaded with antigens from their tumor, and then reinfused. This same strategy could be adapted for prostate cancer patients who have enough fresh tumor tissue after surgery or biopsy. Researchers are also working with patient‑derived samples to see how well human Bvax activates T cells and produces tumor‑reactive antibodies, which would be important for advanced or treatment‑resistant prostate cancers, such as those that come back after hormone therapy or in the metastatic setting. While direct human data in prostate cancer are still lacking, the fact that Bvax can shrink an immune‑excluded prostate tumor in mice and boost immune infiltration suggests it could become a candidate for future prostate‑cancer trials, especially when combined with existing treatments like chemotherapy, radiation, or checkpoint inhibitors.

Source.